{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-067026","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.629100+00:00","generated_at":"2026-05-16T00:40:04.382319+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Standard BioTools Q4 rev $23.8M (-4% YoY); FY2025 rev $85.3M (-6%); guides FY2026 $80-85M","bullets":["Q4 2025 net income from continuing ops $13.9M (includes $38.4M deferred tax release) vs net loss $27.2M YoY.","Full-year 2025 net loss $58.8M vs $90.9M; adjusted EBITDA loss $62.6M vs $64.2M.","FY2026 revenue guidance $80-85M; company expects seasonality similar to prior years.","Cash and investments from continuing ops $210.7M at Dec 31, 2025; ~$550M after SomaLogic close on Jan 30, 2026.","Approximately $1 billion in U.S. federal NOL carryforwards available; usage may be limited."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-067026","json":"https://secwatch.observer/filing/0001193125-26-067026.json","markdown":"https://secwatch.observer/filing/0001193125-26-067026.md","text":"https://secwatch.observer/filing/0001193125-26-067026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000119312526067026/0001193125-26-067026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000119312526067026/lab-20260224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:40:04.382319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}